Identification of old drugs as potential inhibitors of HIV-1 integrase - Human LEDGF/p75 interaction via molecular docking

Journal of Molecular Modeling

Volumn 18, Issue 12, 2012, Pages 4995-5003

  Hu, Guoping ^a   Li, Xi ^a   Sun, Xianqiang ^a   Lu, Weiqiang ^a   Liu, Guixia ^a   Huang, Jin ^a   Shen, Xu ^b   Tang, Yun ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Drug repositioning; HIV 1 integrase; Human LEDGF p75 protein; Molecular docking; Protein protein interaction

Indexed keywords

ARGATROBAN; ATORVASTATIN; BEZAFIBRATE; BUMETANIDE; CANDESARTAN; CARBIDOPA; DICLOFENAC; DIFLUNISAL; ENOXACIN; EPROSARTAN; FENOPROFEN; FLUINDOSTATIN; FLURBIPROFEN; IBUPROFEN; INTEGRASE; INTEGRASE INHIBITOR; KETOPROFEN; LENS EPITHELIUM DERIVED GROWTH FACTOR; LOMEFLOXACIN; MONTELUKAST; NALIDIXIC ACID; NAPROXEN; NIFLUMIC ACID; OLOPATADINE; PROTEIN P75; SULINDAC; TAZOBACTAM; TELMISARTAN; TOLMETIN;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; LIFE CYCLE; MOLECULAR DOCKING; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; VIRUS INHIBITION; VIRUS REPLICATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BINDING SITES; DRUG DISCOVERY; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INHIBITORY CONCENTRATION 50; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; ROC CURVE; SURFACE PROPERTIES; THERMODYNAMICS; TRANSCRIPTION FACTORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84870607167     PISSN: 16102940     EISSN: 09485023     Source Type: Journal    
DOI: 10.1007/s00894-012-1494-0     Document Type: Article

References (34)

1. Anthony NJ (2004) HIV-1 integrase: a target for new AIDS chemotherapeutics. Curr Top Med Chem 4:979-990.
2. Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, Tchertanov L, Peytavin G, Reynes J, Mouscadet JF, Katlama C, Calvez V, Marcelin AG (2008) Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 52:1351-1358. doi:10.1128/Aac.01228-07.
3. Van Maele B, Busschots K, Vandekerckhove L, Christ F, Debyser Z (2006) Cellular co-factors of HIV-1 integration. Trends Biochem Sci 31:98-105. doi:10.1016/j.tibs.2005.12.002.
4. Llano M, Saenz DT, Meehan A, Wongthida P, Peretz M, Walker WH, Teo WL, Poeschla EM (2006) An essential role for LEDGF/p75 in HIV integration. Science 314:461-464. doi:10.1126/science.1132319.
5. Vanegas M, Llano M, Delgado S, Thompson D, Peretz M, Poeschla E (2005) Identification of the LEDGF/p75 HIV-1 integraseinteraction domain and NLS reveals NLS-independent chromatin tethering. J Cell Sci 118:1733-1743. doi:10.1242/jcs.02299.
6. Al-Mawsawi LQ, Neamati N (2007) Blocking interactions between HIV-1 integrase and cellular cofactors: an emerging antiretroviral strategy. Trends Pharmacol Sci 28:526-535. doi:10.1016/j.tips.2007.09.005.
7. Poeschla EM (2008) Integrase, LEDGF/p75 and HIV replication. Cell Mol Life Sci 65:1403-1424. doi:10.1007/s00018-008-7540-5.
8. De Rijck J, Vandekerckhove L, Gijsbers R, Hombrouck A, Hendrix J, Vercammen J, Engelborghs Y, Christ F, Debyser Z (2006) Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication. J Virol 80:11498-11509. doi:10.1128/Jvi.00801-06.
9. Cherepanov P, Ambrosio ALB, Rahman S, Ellenberger T, Engelman A (2005) Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc Natl Acad Sci USA 102:17308-17313. doi:10.1073/pnas. 0506921402.
10. Arkin MR, Wells JA (2004) Small-molecule inhibitors of proteinprotein interactions: Progressing towards the dream. Nat Rev Drug Discovery 3:301-317. doi:10.1038/Nrd1343.
11. Du L, Zhao YX, Chen J, Yang LM, Zheng YT, Tang Y, Shen X, Jiang HL (2008) D77, one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75. Biochem Biophys Res Commun 375:139-144. doi:10.1016/j.bbrc.2008.07.139.
12. De Luca L, Barreca ML, Ferro S, Christ F, Iraci N, Gitto R, Monforte AM, Debyser Z, Chimirri A (2009) Pharmacophorebased discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75. Chem Med Chem 4:1311-1316. doi:10.1002/cmdc.200900070.
13. Christ F, Voet A, Marchand A, Nicolet S, Desimmie BA, Marchand D, Bardiot D, Van der Veken NJ, Van Remoortel B, Strelkov SV, De Maeyer M, Chaltin P, Debyser Z (2010) Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 6:442-448. doi:10.1038/Nchembio.370.
14. De Luca L, Ferro S, Gitto R, Barreca ML, Agnello S, Christ F, Debyser Z, Chimirri A (2010) Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor. Bioorg Med Chem 18:7515-7521. doi:10.1016/j.bmc.2010.08.051.
15. De Luca L, Ferro S, Morreale F, De Grazia S, Chimirri A (2011) Inhibitors of the Interactions between HIV-1 IN and the Cofactor LEDGF/p75. Chem Med Chem 6:1184-1191. doi:10.1002/cmdc.201100071.
16. Prime, version 2.1, Schrödinger, LLC, New York, NY, 2009.
17. MacroModel, version 9.7, Schrödinger, LLC, New York, NY, 2009.
18. Accelrys Software Inc., Discovery Studio Modeling Environment, Release 2.5, Accelrys, Inc, San Diego, CA, USA, 2004, http://accelrys.com/.
19. Fang J, Shen J, Cheng FX, Xu ZJ, Liu GX, Tang Y (2011) Computational insights into ligand selectivity of estrogen receptors from pharmacophore modeling. Mol Inform 30:539-549. doi:10.1002/minf.201000170.
20. Kuang GL, Hu GP, Sun XQ, Li WH, Liu GX, Tang Y (2012) In silico investigation of interactions between human cannabinoid receptor-1 and its antagonists. J Mol Model. doi:10.1007/s00894- 012-1381-8.
21. Hu GP, Kuang GL, Xiao W, Li WH, Liu GX, Tang Y (2012) Performance evaluation of 2D fingerprint and 3D shape similarity methods in virtual screening. J Chem Inf Model. doi:10.1021/ci300030u.
22. Jahn A, Hinselmann G, Fechner N, Zell A (2009) Optimal assignment methods for ligand-based virtual screening. J Chem Inf 1:14. doi:10.1186/1758-2946-1- 14.
23. Jain AN, Nicholls A (2008) Recommendations for evaluation of computational methods. J Comput Aided Mol Des 22:133-139. doi:10.1007/s10822- 008-9196-5.
24. LigPrep, version 2.3, Schrödinger, LLC, New York, NY, 2009.
25. Glide, version 5.5, Schrödinger, LLC, New York, NY, 2009.
26. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739-1749. doi:10.1021/jm0306430.
27. Brooijmans N, Humblet C (2010) Chemical space sampling by different scoring functions and crystal structures. J Comput Aided Mol Des 24:433-447. doi:10.1007/s10822-010-9356-2.
28. Jenkins TM, Engelman A, Ghirlando R, Craigie R (1996) A soluble active mutant of HIV-1 integrase: involvement of both the core and carboxyl-terminal domains in multimerization. J Biol Chem 271:7712-7718.
29. Hou Y, McGuinness DE, Prongay AJ, Feld B, Ingravallo P, Ogert RA, Lunn CA, Howe JA (2008) Screening for antiviral inhibitors of the HIV integrase - LEDGF/p75 interaction using the AlphaScreen (TM) luminescent proximity assay. J Biomol Screening 13:406-414. doi:10.1177/1087057108317060.
30. Zhao Y, Li W, Zeng J, Liu G, Tang Y (2008) Insights into the interactions between HIV-1 integrase and human LEDGF/p75 by molecular dynamics simulation and free energy calculation. Proteins 72:635-645. doi:10.1002/prot.21955.
31. Busschots K, Voet A, De Maeyer M, Rain JC, Emiliani S, Benarous R, Desender L, Debyser Z, Christ F (2007) Identification of the LEDGF/p75 binding site in HIV-1 integrase. J Mol Biol 365:1480- 1492. doi:10.1016/j.jmb.2006.10. 094.
32. Penzak SR, Chuck SK (2000) Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis 32:111-123.
33. Del Real G, Jimenez-Baranda S, Mira E, Lacalle RA, Lucas P, Gomez-Mouton C, Alegret M, Pena JM, Rodriguez-Zapata M, Alvarez-Mon M, Martinez-A C, Manes S (2004) Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 200:541-547. doi:10.1084/Jem.20040061.
34. Giguere JF, Tremblay MJ (2004) Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol 78:12062-12065. doi:10.1128/Jvi.78.21.12062-12065. 2004.